A Study of Imlifidase in Patients With Guillain-Barré Syndrome
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The study participants are patients which have been diagnosed with Guillain-Barré Syndrome
(GBS) and are planned to receive treatment with intravenous immunoglobulin (IVIg). IVIg is a
standard of care treatment for GBS patients. The patients in this study will be treated with
the study medicine imlifidase on day 1, and with IVIg on days 3-7.
The purpose of this study is to investigate the safety and effectiveness of imlifidase in
patients diagnosed with GBS.